HASBROUCK HEIGHTS, N.J., June 2, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report on the presentation of new positive data at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Francisco. The symposium was held between 6:00 and 7:00 pm EDT on Tuesday. The well-attended symposium highlighted the ongoing clinical development program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH) and featured expert panel discussions on the new therapy. The symposium, "Progress with NX-1207: Phase 3 Pro-Apoptotic Injectable for BPH," was chaired by Neal Shore, MD, FACS of Myrtle Beach, SC. Panel members included Barrett Cowan, MD, FACS of Denver, CO, Barton Wachs, MD, FACS of Long Beach, CA, and Christopher Threatt, MD of Atherton, CA. A new research report was presented at the NX-1207 symposium, authored by Dr. Barrett Cowan, Dr. Kevin Cline of Shreveport, LA, Dr. Sheldon Freedman of Las Vegas, NV, Dr. Pat Hezmall of Arlington, TX, Dr. Barton Wachs, Dr. Chris Threatt, and Dr. Neal Shore. The new data concerned outcome analyses of single-injection NX-1207 in 51 patients. Subjects in the NX-1207 2.5 mg cohort had mean improvements in their BPH symptoms that reached statistical significance (p < .0001). According to the report, "NX-1207 is an office-based procedure involving only a few minutes to administer associated with minimal discomfort and no catheter requirement", and "results indicate statistically significant symptomatic improvement and a very acceptable safety profile". According to Dr. Shore, "If approved, NX-1207 will certainly change the landscape of how we treat BPH symptoms and would set the standard for office-based therapy for BPH." Dr. Shore is a well known U.S. clinical investigator and expert in prostate diseases. Dr. Wachs said, "NX-1207 appears to be a quicker and more effective option than current treatments and adds a different dimension to the treatment of BPH. This is a drug for urologists." Dr. Wachs is a highly respected urologist who is the recipient of numerous awards, including the Physician Recognition Award presented by the American Medical Association.
Dr. Cowan added, "Durability is a key factor and a single injection of NX-1207 has been shown to have durable benefits." Dr. Cowan is a well known clinical investigator and an Adjunct Faculty member at the University of Colorado Health Sciences.According to Dr. Threatt, "This agent will be a game changer in the field of men's health." Dr. Threatt is the Medical Director of Peninsula Urology and has received multiple awards for his professional activities as a urologist. NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials where a single dose of NX-1207 has been found to produce symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs. Follow-up studies have shown evidence of long lasting benefit with a significant proportion of men who received a single dose reporting maintained improvement in BPH symptoms without other treatments for up to 6 ½ years. NX-1207 has entered its Phase 3 development program, the last stage before filing with the FDA for approval. NX-1207 is injected by a urologist in an office setting and involves little or no pain or discomfort. For more information about the NX-1207 Phase 3 clinical trials please go to www.clinicaltrials.gov or contact Nymox at firstname.lastname@example.org. BPH treatment represents a growing market with more than 100 million men worldwide being estimated to suffer from BPH symptoms. The disorder is a common affliction of older men, affecting approximately half of men over age 50 and close to 90% of men by age 80, and is associated with growth in prostate size as men age. More information about Nymox is available at www.nymox.com, email: email@example.com, or 800-936-9669. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: Nymox Pharmaceutical Corporation Roy Wolvin 1-800-93NYMOX www.nymox.com